Somatostatine analogs (SSAs) are currently indicated in the treatment of acromegaly and neuroendocrine tumors (NETs). Actually, pregnancy in patients with acromegaly and NETs does not represent an exceptional event because reproductive behavior has changed in the last decades and patients with NETs show more frequently long-term survival. The safety profile of SSAs during pregnancy is still controversial. Concerning acromegaly, based on case reports and series, SSAs administration during pregnancy seems to be relatively well tolerated. Concerning patients with NETs, up to date only one patient with NET receiving SSA during pregnancy has been reported in literature. We report two cases of gastroenteropancreatic-NET patients receiving SSA lanreotide for the entire course of their pregnancy, with favorable outcomes for both mothers and babies. Our experience supports the possibility to continue safely SSA lanreotide during pregnancy in patients with NET.

Somatostatin analogs in pregnant patients with neuroendocrine tumor / Meoni, Giulia; Giommoni, Elisa; Petreni, Paolo; Pillozzi, Serena; Mazzoni, Francesca; Pellegrini, Elisa; Brugia, Marco; Lunghi, Alice; Muto, Andrea; Antonuzzo, Lorenzo. - In: ANTI-CANCER DRUGS. - ISSN 1473-5741. - STAMPA. - 31:(2020), pp. 1096-1098. [10.1097/CAD.0000000000000967]

Somatostatin analogs in pregnant patients with neuroendocrine tumor

Giommoni, Elisa;Petreni, Paolo;Pillozzi, Serena;Pellegrini, Elisa;Brugia, Marco;Antonuzzo, Lorenzo
2020

Abstract

Somatostatine analogs (SSAs) are currently indicated in the treatment of acromegaly and neuroendocrine tumors (NETs). Actually, pregnancy in patients with acromegaly and NETs does not represent an exceptional event because reproductive behavior has changed in the last decades and patients with NETs show more frequently long-term survival. The safety profile of SSAs during pregnancy is still controversial. Concerning acromegaly, based on case reports and series, SSAs administration during pregnancy seems to be relatively well tolerated. Concerning patients with NETs, up to date only one patient with NET receiving SSA during pregnancy has been reported in literature. We report two cases of gastroenteropancreatic-NET patients receiving SSA lanreotide for the entire course of their pregnancy, with favorable outcomes for both mothers and babies. Our experience supports the possibility to continue safely SSA lanreotide during pregnancy in patients with NET.
2020
31
1096
1098
Meoni, Giulia; Giommoni, Elisa; Petreni, Paolo; Pillozzi, Serena; Mazzoni, Francesca; Pellegrini, Elisa; Brugia, Marco; Lunghi, Alice; Muto, Andrea; Antonuzzo, Lorenzo
File in questo prodotto:
File Dimensione Formato  
Somatostatin_analogs_in_pregnant_patients_with.14.pdf

Open Access dal 01/01/2022

Tipologia: Pdf editoriale (Version of record)
Licenza: Tutti i diritti riservati
Dimensione 266.64 kB
Formato Adobe PDF
266.64 kB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1287134
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 4
social impact